Fungus in the Brain: Symptoms, Causes, and Treatments

Fungal infections of the brain are rare but among the most dangerous infections a person can develop, with mortality rates that remain high even with modern treatment. The fungi most commonly responsible include Cryptococcus, Aspergillus, Candida, and a group of molds called Mucorales, and they typically reach the brain through the bloodstream after entering the body through the lungs or an open wound.¹ Because symptoms often look identical to bacterial meningitis or even tuberculosis, diagnosis is frequently delayed, and the blood-brain barrier makes delivering antifungal drugs to the infection site uniquely difficult.

Which Fungi Infect the Brain

A handful of fungal species account for the vast majority of brain infections. Cryptococcus neoformans is the most common culprit worldwide, particularly in people living with HIV. Aspergillus fumigatus tends to strike people whose immune systems are suppressed by chemotherapy or organ transplant medications. Candida species, which many people associate with yeast infections of the skin or mouth, can invade the brain in hospitalized patients, especially those with central venous catheters or prolonged ICU stays. The Mucorales group, responsible for the condition sometimes called mucormycosis or “black fungus,” often enters through the sinuses and can spread directly into brain tissue. Dimorphic fungi, which shift shape depending on temperature, and dark-pigmented molds round out the list.¹ Each of these organisms behaves differently once inside the brain, which is part of what makes treatment so complicated.

How Fungi Get Past the Blood-Brain Barrier

The brain is protected by a tightly sealed network of blood vessels known as the blood-brain barrier. This barrier is remarkably effective at keeping pathogens out, which is why brain infections of any kind are relatively uncommon. But certain fungi have evolved clever strategies to slip through.

Cryptococcus neoformans uses at least two known routes. In one, the fungal cells cluster together and pass directly through the cells lining brain blood vessels without breaking open the tight junctions between those cells, a process researchers have observed using lab-on-a-chip models of the human blood-brain barrier.² In the second, the fungus hitches a ride inside immune cells. White blood cells that have swallowed the fungus cross the barrier through natural pores in the vessel wall, essentially smuggling the pathogen into the brain like a Trojan horse. Researchers have directly imaged this process, watching immune cells carrying live Cryptococcus pass through the barrier.³

Other fungi take different paths. Aspergillus tends to spread through the bloodstream from a lung infection, while Mucorales often invade from neighboring sinus tissue, growing directly through bone and into the brain. Traumatic injuries that break the skull can also introduce fungi that would never otherwise reach the central nervous system.¹

Who Is Most Vulnerable

A healthy immune system is remarkably good at keeping inhaled fungal spores from causing serious disease. Most people breathe in Cryptococcus or Aspergillus spores at some point without ever getting sick. The infections that reach the brain almost always occur in people whose immune defenses are compromised. As the use of immunosuppressive therapies, organ transplants, and chemotherapy has expanded in modern medicine, so has the incidence of invasive fungal infections that can spread to the brain.⁴

The highest-risk groups include:

People with advanced HIV/AIDS: Cryptococcal meningitis remains one of the leading causes of death in this population, particularly in sub-Saharan Africa where access to antiretroviral therapy may be limited.
Transplant recipients: Anti-rejection medications deliberately suppress immunity, creating an opening for opportunistic fungi.
Cancer patients on chemotherapy: Prolonged low white blood cell counts leave the brain vulnerable, especially to Aspergillus.
People with uncontrolled diabetes: Mucormycosis has a strong association with diabetic ketoacidosis, as the high-sugar, acidic blood environment favors fungal growth.
Premature infants: Their immune systems are not yet fully developed, making them susceptible to Candida and Aspergillus infections that can spread to the brain.

Occasionally, though, brain fungal infections appear in people with no obvious immune problem. Some dark-pigmented molds like Cladophialophora bantiana have a particular affinity for brain tissue and can cause abscesses even in otherwise healthy individuals.⁵

Symptoms and How They Show Up

Fungal brain infections do not announce themselves with a unique set of symptoms. The clinical picture overlaps heavily with bacterial meningitis, tuberculosis, and even brain tumors, which is a major reason these infections are so often caught late. The most common presentations include meningitis (inflammation of the membranes around the brain), brain abscesses (pockets of infection within brain tissue), and hydrocephalus (a dangerous buildup of fluid that raises pressure inside the skull).⁶

In cryptococcal meningitis, the most widespread form of fungal brain infection, the fungus accumulates in the fluid-filled spaces around the brain and along blood vessels, physically blocking the normal flow and drainage of cerebrospinal fluid. This drives up intracranial pressure, which is responsible for many of the worst symptoms.⁷ In one large study, nearly half of patients with HIV-associated cryptococcal meningitis had dangerously elevated opening pressures at the time of diagnosis.⁸

Symptoms you might expect across the various forms of fungal brain infection include:

Headache: Often severe and persistent, driven by rising pressure inside the skull.
Fever: Present in many cases, though sometimes low-grade or intermittent.
Altered mental status: Confusion, drowsiness, personality changes, or difficulty concentrating.
Nausea and vomiting: Especially when intracranial pressure is high.
Vision problems: Raised pressure can compress the optic nerves, and both high fungal burden and elevated pressure are independently linked to vision loss in cryptococcal meningitis.⁸
Seizures: Particularly when abscesses or inflammation irritate brain tissue.
Stroke-like episodes: Fungal infections can cause inflammation of blood vessel walls, leading to blockages or bleeding.

Mucormycosis affecting the sinuses and brain has its own distinctive pattern: facial pain, swelling around the eye, black tissue on the palate or inside the nose, and rapid neurological decline. The disease can progress over days rather than weeks.

Why It Is So Often Misdiagnosed

Because fungal meningitis can look nearly identical to tuberculosis on both clinical examination and brain imaging, misdiagnosis is a well-documented problem. In one reported case, a patient with a brain abscess caused by the dark mold Cladophialophora bantiana was initially diagnosed with a tuberculoma based on imaging and started on tuberculosis drugs before the true cause was identified.⁹ This kind of confusion is especially common in regions where tuberculosis is prevalent, because clinicians reasonably reach for the more likely diagnosis first.

The overlap extends to imaging. On MRI, fungal brain abscesses can share features with bacterial abscesses, tumors, and granulomas caused by tuberculosis. However, fungal abscesses do have some characteristic MRI findings that can raise suspicion: they tend to show irregular walls with non-enhancing projections pointing inward from the abscess wall, features that carry a high probability of fungal origin when combined with restricted water movement on diffusion-weighted imaging.¹⁰ Even so, imaging alone is rarely definitive, and confirming a fungal cause usually requires sampling the cerebrospinal fluid or the abscess material itself.

Getting to a Diagnosis

Diagnosis typically starts with a lumbar puncture, where cerebrospinal fluid is drawn and tested for signs of infection. For cryptococcal meningitis, a rapid antigen test on the fluid is highly reliable and widely available. For other fungi, culture remains the gold standard, though it can take days to weeks for molds to grow.

A biomarker called beta-d-glucan, a component of most fungal cell walls, can be measured in cerebrospinal fluid as a nonspecific indicator that a fungal infection is present. A systematic review found that its sensitivity varies considerably depending on the organism: it performed well in an outbreak of meningitis caused by Exserohilum rostratum (over 95% sensitivity) and reasonably well in cryptococcal meningitis (about 89% sensitivity), but was less reliable for Histoplasma meningitis (roughly 53% sensitivity).¹¹ Because of this variability, beta-d-glucan testing works best as a supplementary tool alongside organism-specific tests rather than a standalone diagnostic.

Brain imaging with MRI is essential for detecting abscesses, masses, or complications like hydrocephalus. Fungal infections can cause meningitis, blood vessel inflammation, and space-occupying lesions that all require different management approaches, so imaging helps map the extent of the problem.¹²

Drug Treatment and the Blood-Brain Barrier Problem

Treating a fungal infection anywhere in the body is harder than treating a bacterial one. Fungi are eukaryotic organisms, meaning their cells are built much more like human cells than bacteria are. That similarity limits the drug targets available: you cannot simply poison the fungus without risking damage to the patient’s own cells. When the infection is in the brain, an additional obstacle emerges: the very blood-brain barrier the fungus managed to cross now blocks many antifungal drugs from reaching therapeutic levels at the infection site.

Four main classes of antifungal drugs are used for brain infections: polyenes, triazoles, pyrimidine analogues, and echinocandins. Each penetrates the brain differently.¹³ Amphotericin B, a polyene, has been the backbone of treatment for cryptococcal meningitis for decades. It is given intravenously, often in a lipid-coated formulation that reduces kidney damage. Flucytosine, a pyrimidine analogue, penetrates the brain well and is usually combined with amphotericin B during the initial intensive phase of treatment.

For brain infections caused by Aspergillus, voriconazole, a triazole antifungal, is the preferred choice because of its ability to cross the blood-brain barrier and achieve effective concentrations in brain tissue.¹⁴ Echinocandins like caspofungin have traditionally been considered poor candidates for brain infections because they do not cross the barrier easily. However, animal research has found that caspofungin does reach potentially useful concentrations in brain tissue and significantly improved survival in rats with brain aspergillosis, suggesting the conventional wisdom deserves a second look.¹⁵

Treatment courses are long. In a study of children with cancer who developed fungal brain infections, the average duration of antifungal therapy was 130 days, with some patients treated for nearly a year.¹⁶ The drugs are expensive, many have serious side effects including kidney damage and liver toxicity, and patients often need close monitoring with blood tests throughout treatment.

When Surgery Becomes Necessary

Antifungal drugs alone are often not enough, especially when the infection creates a mass or abscess that compresses brain tissue. Surgery serves two purposes: it relieves dangerous pressure on the brain and removes infected material that drugs struggle to penetrate. The approach varies. Aspiration, where a needle is guided into the abscess to drain it, is less invasive. Craniotomy, where a section of skull is opened to remove the abscess and its surrounding capsule, allows more thorough clearance.¹⁷

However, fungal brain abscesses do not always respond to the same surgical logic as bacterial ones. One case report described a patient with a Cladophialophora bantiana abscess where repeated surgical excision actually led to continued growth rather than resolution. The treatment team shifted strategy, stopping attempts at complete removal and instead draining the abscess repeatedly while injecting amphotericin B directly into the cavity alongside systemic voriconazole. The rationale was that the abscess capsule itself might serve as part of the body’s defense against the fungus, and destroying it could be counterproductive.⁵ This idea challenges the standard surgical instinct to excise as much as possible and suggests that the best approach for fungal abscesses may be to sterilize the lesion in place rather than cut it out.

In pediatric cases, surgical treatment has been independently associated with improved survival in brain aspergillosis.¹⁸ The decision of whether and how aggressively to operate depends on the size and location of the lesion, the patient’s overall condition, and the specific fungus involved.

Survival and Long-Term Outlook

The prognosis for fungal brain infections is poor compared to bacterial brain infections, though outcomes vary widely depending on the organism and the patient’s immune status. In one cohort study, fungal brain abscesses were an independent predictor of death even after accounting for other clinical factors, with dramatically worse survival compared to bacterial brain abscesses.¹⁹

A review specifically examining fungal brain infections found that overall mortality was about 60%, with half of deaths occurring within the first two months. Aspergillus infections fared worst, often leading to septic blood clots and multi-organ failure. Survivors who did make it frequently had significant disability. The average hospital stay in that series was 37 days.²⁰ The title of that review, “no longer a death sentence,” reflects the fact that survival is improving with better drugs and surgical techniques, but the numbers remain sobering.

Among children with cancer who developed brain fungal infections, three of twelve patients died (25%), two from the infection itself and one from the underlying disease.¹⁶ In a systematic review of brain aspergillosis in children, overall mortality was about 65%, though surgical treatment was linked to better chances of surviving.¹⁸

A Dangerous Paradox After Starting Treatment

For patients with HIV who develop cryptococcal meningitis, starting antiretroviral therapy to rebuild the immune system is life-saving in the long run but creates a paradoxical short-term danger. As the immune system recovers, it can mount an overwhelming inflammatory response against the fungus already present in the brain, a phenomenon called immune reconstitution inflammatory syndrome, or IRIS. In the brain, this looks like a sudden worsening of meningitis symptoms: spiking headaches, confusion, fever, and rising intracranial pressure, all of which can mimic the original infection returning.

Central nervous system IRIS develops in anywhere from 9% to 47% of HIV-positive patients with a brain opportunistic infection who start antiretroviral therapy, and the associated mortality ranges from 13% to 75% depending on the pathogen involved.²¹ Because the symptoms closely resemble treatment failure or a new infection, distinguishing IRIS from these other possibilities requires careful clinical judgment. This is one reason guidelines recommend delaying antiretroviral therapy for several weeks after starting antifungal treatment in patients with cryptococcal meningitis, giving the drugs time to reduce the amount of fungus before the immune system ramps up.

The Candida auris Problem

Candida auris is a fungal pathogen that has generated alarm in recent years because of its high rates of resistance to multiple classes of antifungal drugs. While it is best known for bloodstream and wound infections in hospital settings, it can also infect the central nervous system, though this remains uncommon. It is concerning enough that when it does reach the brain, treatment options are severely limited.

One published case described a successful outcome treating a C. auris cerebrospinal fluid shunt infection with caspofungin delivered directly into the brain’s ventricles.²² Another case involved a teenager who developed a brain infection with multidrug-resistant C. auris after a gunshot wound. Despite systemic antifungal therapy, the cerebrospinal fluid cultures kept coming back positive until intrathecal caspofungin (delivered directly into the spinal fluid) was added to the regimen.²³ These cases highlight a worrying pattern: standard intravenous drugs may not clear resistant organisms from the brain, pushing clinicians toward invasive delivery methods that carry their own risks.

Vascular Complications and Fungal Aneurysms

Fungal infections in the brain do not just cause meningitis and abscesses. They can also attack blood vessel walls, leading to a condition called a mycotic aneurysm, where a weakened arterial wall balloons outward and risks rupturing. The term “mycotic” is a historical holdover that applies to any infection-related aneurysm, whether bacterial or fungal. Stroke-like episodes in a patient with a known fungal infection should raise suspicion for this complication.⁶

When brain fungal infections damage vessel walls in this way, the consequences can be abrupt and catastrophic. Fungal organisms can also cause vasculitis, an inflammation of the blood vessel lining that narrows or blocks arteries, leading to strokes.¹² These vascular complications are another reason early diagnosis and aggressive treatment matter so much: once the vasculature is compromised, the damage may be irreversible even if the infection is controlled.

Climate Change and Shifting Fungal Geography

The landscape of fungal disease is not static. Rising temperatures, shifting rainfall patterns, and more frequent extreme weather events are altering where pathogenic fungi can thrive. Species that were once confined to specific climatic zones are expanding their ranges, and warmer temperatures may be selecting for fungal strains better adapted to survive at human body temperature, which is one of the body’s primary defenses against fungal invasion.²⁴ Coccidioidomycosis (valley fever), once largely limited to the desert Southwest in the United States, has been appearing in areas where it was previously unheard of. Clinicians in regions with no historical experience of certain fungal diseases may be even less likely to consider them in their initial differential diagnosis, compounding the delay problem that already plagues fungal brain infections.

1
PubMed. Fungal Infections of the Central Nervous System
2
Nature Biomedical Engineering. Fungal brain infection modelled in a human-neurovascular-unit-on-a-chip with a functional blood–brain barrier
3
PubMed Central. Trojan Horse Transit Contributes to Blood-Brain Barrier Crossing of a Eukaryotic Pathogen
4
PubMed Central. It’s all in your head: antifungal immunity in the brain
5
PubMed Central. Fungal brain abscess caused by “Black Mold” (Cladophialophora bantiana) – A case report of successful treatment with an emphasis on how fungal brain abscess may be different from bacterial brain abscess
6
PubMed. Fungal infections of the nervous system: current perspective and controversies in management
7
PubMed Central. Elevated Intracranial Pressure in Cryptococcal Meningoencephalitis: Examining Old, New, and Promising Drug Therapies
8
PubMed Central. Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis
9
PubMed Central. Fatal cerebral phaeohyphomycosis caused by Cladophialophora bantiana mimicking tuberculous brain abscess
10
Neurology India. Imaging features of central nervous system fungal infections
11
PubMed Central. Efficacy of Cerebrospinal Fluid Beta-d-Glucan Diagnostic Testing for Fungal Meningitis: a Systematic Review
12
PubMed Central. Fungal Infections of the Central Nervous System: A Pictorial Review
13
PubMed. Antifungal drugs: An updated review of central nervous system pharmacokinetics
14
PubMed Central. Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy
15
PubMed Central. Caspofungin Cerebral Penetration and Therapeutic Efficacy in Experimental Cerebral Aspergillosis
16
PubMed Central. Central Nervous System Fungal Diseases in Children with Malignancies: A 16-Year Study from the Infection Working Group of the Hellenic Society of Pediatric Hematology Oncology
17
Interdisciplinary Neurosurgery. Complete resection of fungal brain abscess in a patient with chronic active Epstein-Barr virus infection using intraoperative MRI: A case report
18
PubMed. Central nervous system aspergillosis in children: a systematic review of reported cases
19
PubMed. Survival outcomes and prognostic factors of fungal brain abscess: A comparative cohort study
20
PubMed Central. Fungal brain infection—no longer a death sentence
21
PubMed Central. Central nervous system immune reconstitution inflammatory syndrome
22
Medical Mycology Case Reports. Successful treatment of C. auris shunt infection with intraventricular caspofungin
23
PubMed. Intrathecal and systemic antifungal therapy for Candida auris central nervous system infection following gunshot wound-related neurotrauma
24
PubMed Central. Effects of climate change on fungal infections